Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00180531
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : December 13, 2007
Sponsor:
Information provided by:
Guidant Corporation

Brief Summary:
The objective of this study is to evaluate the prevalence of sustained ventricular and supraventricular rhythm disorders in patients implanted with a CONTAK RENEWAL TR2 ventricular resynchronization therapy (CRT) device

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Device: Renewal TR2 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Monitoring of Arrhythmias and Heart Rate Variability in Patients With Congestive Heart Failure Treated With the Cardiac Resynchronisation Pacemaker Renewal TR2
Study Start Date : February 2004
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Occurrence of ventricular arrhythmias
  2. Occurrence of supraventricular arrhythmias


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate or severe chronic heart failure, defined by the presence of NYHA class III or IV symptoms, Intra/interventricular synchronization disorder evaluated by echocardiography and/or Doppler Tissue Imaging (DTI, Yu's method22), Ejection fraction (EF) ≤ 40 %, If previous history of myocardial infarction, MI must be > 60 days from the date of inclusion, Estimated life expectancy > 6 months in the case of concomitant disease, Age ≥ 18 years, Optimal drug treatment of chronic heart failure (according to SFC* recommendations).

Exclusion Criteria:

  • Conventional indication for treatment by implantable defibrillator upon inclusion, Cardiac transplant envisaged within 6 months, Unexplained syncope, MI < 60 days before inclusion, Non compliance to drug treatment for chronic heart failure, Any coronary pathology which may be treated by revascularisation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180531


Locations
Layout table for location information
France
CHG Albi
Albi, France, 81013
CHU Michalon
Grenoble, France, 38043
CH La Croix Rousse
Lyon, France, 69317
Hôpital Louis Pradel
Lyon, France, 69394
Nouvelle Clinique Nantaise
Nantes, France, 44227
CHU Nîmes
Nîmes, France, 30029
CHG Perigueux
Perigueux, France, 24019
Hôpital Pontchaillou
Rennes, France, 35033
Centre Cardiologique du Nord
Saint Denis, France, 93207
Clinique Pasteur
Toulouse, France, 31076
Sponsors and Collaborators
Guidant Corporation
Investigators
Layout table for investigator information
Principal Investigator: P. CHEVALIER, MD Hôpital Louis Pradel, Lyon
Principal Investigator: S Boveda, MD Clinique Pasteur
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Elisabeth Mouton, Guidant France
ClinicalTrials.gov Identifier: NCT00180531    
Other Study ID Numbers: Mona Lisa v. 1.1 3/12/03
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: December 13, 2007
Last Verified: December 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases